疏肝健脾中药配合介入疗法治疗中晚期肝癌的临床研究  

Clinical study of SGJP TCM combined with interventional therapy to treat patients with mid-advanced hepatic carcinoma

作　　者：张海[1] 刘秀芳[1] 赵增虎[1] 李成云[1] 李凤玉[1] 石军[1] 任成波[1] 

机构地区：[1]中国人民解放军第251医院肿瘤诊疗中心,河北张家口075000

出　　处：《中西医结合肝病杂志》2009年第1期16-18,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:探索中西医结合治疗原发性中晚期肝癌的价值。方法:103例原发性肝癌患者随机分为两组:综合治疗组(A组)52例,对照组(B组)51例。A组患者在介入前7天服用疏肝健脾中药,B组患者行单纯介入治疗。结果:A组患者在改善临床症状、提高免疫功能及生活质量、保护肝功能及骨髓功能、AFP下降方面,明显优于B组(P<0.05)。两组近期有效率分别为28.8%、19.6%(P>0.05)。A组、B组1年、3年、5年的生存率分别为55.8%、41.2%、25.0%、19.6%、5.8%、0(P<0.05)。结论:疏肝健脾中药不仅能减轻介入治疗的毒副作用,而且能提高患者生活质量,延长中晚期肝癌的带瘤生存期。Objective： To study the value of Shuganjianpi traditional Chinese medicine （ SGJP TCM） combined with interventional therapy to treat patients with mid-advanced hepatic carcinoma. Methods： One hundred and three patients with primary hepatic carcinoma were randomly divided into two groups： combined group （group A）, gontrol group （group B） . Patients in group A had been taking traditional Chinese medicine since seven days before intervention. Patients in group B were given interventional therapy alone. Results： Two groups had significant difference in improving clinical symptom, raising immunifunction and quality of life, protecting hepatic functions and hemopoietic functions, lowering AFP value （P 〈 0. 05） . The effective rates were 28.8%, 19. 6%, in group A, B respectively （P 〉0. 05） . The survival rate of 1 year, 3 years and 5 years were 55.8%, 41.2%, 25.0%, 19. 6%, 5.8%, 0% respectively in group A, B （ P 〈 0. 05 ） . Conclusion： SGJP traditional Chinese medicine could lower side reaction of interventional therapy, improve quality of life, prolong life span of patients of mid-advanced hepatic carcinoma with tumor.

关 键 词：肝癌 介入治疗 疏肝健脾 中药 

分 类 号：R735.7[医药卫生—肿瘤]